Resumen de acción BLUE * bluebird bio, Inc. es una empresa de biotecnología que investiga, desarrolla y comercializa en Estados Unidos terapias génicas para curar enfermedades genéticas graves. Saber más
Recompensas Análisis de riesgos + 1 riesgos adicionales
Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de bluebird bio, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del bluebird bio Precios históricos de las acciones Precio actual de la acción US$186.96 Máximo en las últimas 52 semanas US$500.00 Mínimo de 52 semanas US$180.00 Beta 0.73 Cambio en 1 mes -6.52% Variación en 3 meses -6.52% Cambio de 1 año n/a Variación en 3 años -95.55% Variación en 5 años -99.33% Variación desde la OPV -99.60%
Noticias y actualizaciones recientes
Insufficient new directors Dec 11 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05 Ver más actualizaciones
Insufficient new directors Dec 11 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
bluebird bio, Inc., Annual General Meeting, Nov 06, 2024 Sep 19
bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Aug 25 bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024
bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024 May 30 bluebird bio, Inc. announced delayed 10-Q filing May 17
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy May 07
Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc Mar 29 bluebird bio, Inc. announced delayed annual 10-K filing Mar 27
Chief Medical Officer recently sold Mex$176k worth of stock Mar 10
Chief Medical Officer recently sold Mex$176k worth of stock Mar 08 bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 21
bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 20
bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Dec 19
Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events
Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition Nov 03
bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events Jun 22
Less than half of directors are independent Apr 12
Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021) Mar 31
Less than half of directors are independent Mar 30
Less than half of directors are independent Feb 17
bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer Jan 04
U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18 Dec 20
Less than half of directors are independent Dec 16
Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition Dec 13
An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million. Dec 02 bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer
Less than half of directors are independent Oct 17 bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) Sep 17 bluebird bio, Inc. Announces Executive Changes
Treasurer recently sold Mex$1.6m worth of stock Aug 25
bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Aug 18
President recently sold Mex$1.9m worth of stock Aug 10
Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021) Aug 07
bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022 Aug 06
Chief Regulatory Officer recently sold Mex$140k worth of stock Jul 15
Less than half of directors are independent Jul 05
bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy Jun 11
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy Jun 10
Chief Commercial Officer recently sold Mex$226k worth of stock Jun 08
Less than half of directors are independent Jun 01
bluebird bio, Inc., Annual General Meeting, Jun 22, 2022 May 03 Bluebird Bio, Inc. Announces Executive Changes
bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022 Mar 06 bluebird bio, Inc. announced delayed annual 10-K filing Mar 03
Less than half of directors are independent Mar 01
bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer Feb 05
Less than half of directors are independent Feb 04
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD) Jan 19
Insider recently sold Mex$80k worth of stock Jan 15
bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022 Jan 12
Insider recently sold Mex$637k worth of stock Jan 08
Less than half of directors are independent Dec 29
bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program Dec 21
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor Dec 19
CEO & Director recently sold Mex$179k worth of stock Dec 14
bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy Dec 13
New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels Dec 12
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28 Rentabilidad de los accionistas BLUE * MX Biotechs Mercado MX 7D 0% 0% 0% 1Y n/a 0% 0%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de BLUE * en comparación con la industria MX Biotechs.
Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de BLUE * frente al mercado MX.
Volatilidad de los precios Is BLUE *'s price volatile compared to industry and market? BLUE * volatility BLUE * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Precio estable de las acciones: El precio de las acciones de BLUE * ha sido volátil durante los últimos 3 meses en comparación con el mercado MX.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BLUE * en el último año.
Acerca de la empresa bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa en Estados Unidos terapias génicas para enfermedades genéticas graves curativas. Los productos candidatos de la empresa para enfermedades genéticas graves incluyen ZYNTEGLO (betibeglogene autotemcel) para el tratamiento de la ß-talasemia dependiente de transfusión; lovotibeglogene autotemcel para el tratamiento de la anemia falciforme (ECF); y SKYSONA (elivaldogene autotemcel) para tratar la adrenoleucodistrofia cerebral. Sus programas de desarrollo clínico incluyen HGB-205, HGB-206 y HGB-210 para evaluar la seguridad y eficacia de lovo-cel en el tratamiento de pacientes con ECF; y HGB-204, HGB-205, HGB-207 y HGB-212 para evaluar la seguridad y eficacia de beti-cel en el tratamiento de pacientes con ß-talasemia.
Mostrar más Resumen de fundamentos de bluebird bio, Inc. ¿Cómo se comparan los beneficios e ingresos de bluebird bio con su capitalización de mercado? Estadísticas fundamentales de BLUE * Capitalización bursátil Mex$1.84b Beneficios(TTM ) -Mex$6.05b Ingresos (TTM ) Mex$1.10b
1.7x Ratio precio-ventas (PS)
-0.3x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de BLUE * Ingresos US$53.12m Coste de los ingresos US$78.78m Beneficio bruto -US$25.66m Otros gastos US$267.16m Beneficios -US$292.82m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -30.12 Margen bruto -48.31% Margen de beneficio neto -551.25% Ratio deuda/patrimonio -1,394.4%
¿Cómo se ha desempeñado BLUE * a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/05 06:36 Precio de las acciones al final del día 2024/12/19 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas bluebird bio, Inc. está cubierta por 33 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Jack Allen Baird Huidong Wang Barclays Zhiqiang Shu Berenberg
Mostrar 30 más analistas 
